These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8277912)

  • 21. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group.
    Sweet RL; Roy S; Faro S; O'Brien WF; Sanfilippo JS; Seidlin M
    Obstet Gynecol; 1994 Feb; 83(2):280-6. PubMed ID: 8290195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.
    Siami G; Christou N; Eiseman I; Tack KJ;
    Antimicrob Agents Chemother; 2001 Feb; 45(2):525-31. PubMed ID: 11158750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comprehensive evaluation of pharmacokinetic and clinical studies on tazobactam/piperacillin in pediatric field].
    Fujii R; Okuno A; Fujita K; Yoshikawa M; Inyaku F; Takimoto M; Saijo M; Wagatsuma S; Fukushima N; Ishikawa A
    Jpn J Antibiot; 1995 Mar; 48(3):311-45. PubMed ID: 7752448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A reminder: piperacillin/tazobactam is not for Pseudomonas.
    Med Lett Drugs Ther; 1994 Nov; 36(936):110. PubMed ID: 7968784
    [No Abstract]   [Full Text] [Related]  

  • 26. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.
    Eur J Surg Suppl; 1994; (573):61-6. PubMed ID: 7524798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin.
    Alston WK; Ahern JW
    J Antimicrob Chemother; 2004 Mar; 53(3):549-50. PubMed ID: 14963072
    [No Abstract]   [Full Text] [Related]  

  • 28. [Fundamental and clinical studies on tazobactam/piperacillin in the pediatric field].
    Kitamura K; Nishimori H; Ihara T; Kamiya H
    Jpn J Antibiot; 1998 Jun; 51(6):407-12. PubMed ID: 9755830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pH on antibiotics used to treat anaerobic infection.
    Winstanley TG; Wilcox MH; Spencer RC
    J Antimicrob Chemother; 1992 May; 29(5):594-5. PubMed ID: 1320606
    [No Abstract]   [Full Text] [Related]  

  • 30. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.
    Del Favero A; Menichetti F; Martino P; Bucaneve G; Micozzi A; Gentile G; Furno P; Russo D; D'Antonio D; Ricci P; Martino B; Mandelli F;
    Clin Infect Dis; 2001 Oct; 33(8):1295-301. PubMed ID: 11565068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam.
    Sulahian A; Touratier S; Ribaud P
    N Engl J Med; 2003 Dec; 349(24):2366-7. PubMed ID: 14668472
    [No Abstract]   [Full Text] [Related]  

  • 32. [Drugs: piperacillin/tazobactam].
    Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):132-3. PubMed ID: 7711129
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.
    Gavin PJ; Suseno MT; Thomson RB; Gaydos JM; Pierson CL; Halstead DC; Aslanzadeh J; Brecher S; Rotstein C; Brossette SE; Peterson LR
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2244-7. PubMed ID: 16723596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
    Graham DR; Lucasti C; Malafaia O; Nichols RL; Holtom P; Perez NQ; McAdams A; Woods GL; Ceesay TP; Gesser R
    Clin Infect Dis; 2002 Jun; 34(11):1460-8. PubMed ID: 12015692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implications of revised piperacillin-tazobactam breakpoints in CLSI M-100 S32.
    Dash D; Rai S
    Indian J Med Microbiol; 2023; 42():108-109. PubMed ID: 36241530
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
    Pillay T; Pillay DG; Adhikari M; Sturm AW
    Am J Perinatol; 1998 Jan; 15(1):47-51. PubMed ID: 9475688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre in vitro evaluation of piperacillin/tazobactam in Germany.
    Grimm H
    Eur J Surg Suppl; 1994; (573):25-9. PubMed ID: 7524792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic evaluation of piperacillin-tazobactam.
    Hayashi Y; Roberts JA; Paterson DL; Lipman J
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.